Article info
Original research
Cognitive complaints during breast cancer endocrine therapy: aromatase inhibitors versus tamoxifen
- Correspondence to Dr Ichrak Ben Abdallah, Medical Oncology, University of Tunis El Manar Faculty of Medicine of Tunis, Tunis 2074, Tunisia; benabdallah.ichrak.1212{at}gmail.com
Citation
Cognitive complaints during breast cancer endocrine therapy: aromatase inhibitors versus tamoxifen
Publication history
- Received September 13, 2021
- Accepted March 16, 2022
- First published April 5, 2022.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.